Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Nobuhiko Nakagawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2095-1308; OpenAlex author ID A5031719525. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 4 papers · 2026: 5 papers

Papers 12

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Clinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (… Co-author DOI 10.1002/ijc.70801↗
  3. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  4. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  5. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  6. Long-term outcomes of prophylactic right-half dissection of the superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic ductal adenocar… Co-author DOI 10.1007/s00595-025-03062-6↗
  7. FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (G… Co-author DOI 10.1093/bjs/znaf049↗
  8. Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Nab-Paclitaxel-Treated Unresectable or Rec… Co-author DOI 10.1097/mpa.0000000000002446↗
  9. Exploration of Lipid Mediators for Therapeutic Monitoring of Pancreatic Cancer Patients. Co-author DOI 10.21873/anticanres.17520↗
  10. Genome-wide microRNA Analysis Identified miR-210-3p Over-expression in Pancreatic Cancer Tissues as a Predictor of their Local Invasiveness. Co-author DOI 10.21873/anticanres.17297↗
  11. Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08047-7↗
  12. ASO Author Reflections: The Naples Prognostic Score Predicts Long-Term Survival in Patients with Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08056-6↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tomohisa Otsu · 6 shared papers, 2024–2026 · strength 1.27
  2. Mitsuro Kanda · 6 shared papers, 2020–2026 · strength 1.17
  3. Masamichi Hayashi · 6 shared papers, 2020–2026 · strength 1.17
  4. Yasuhiro Kodera · 6 shared papers, 2020–2025 · strength 1.11
  5. Junpei Yamaguchi · 4 shared papers, 2025–2026 · strength 0.87
  6. Keizo Fujita · 4 shared papers, 2024–2026 · strength 0.85
  7. Yukihiro Yokoyama · 3 shared papers, 2026 · strength 0.67
  8. Tsutomu Fujii · 3 shared papers, 2025–2026 · strength 0.67
  9. So Yamaki · 3 shared papers, 2025–2026 · strength 0.65
  10. Sohei Satoi · 3 shared papers, 2025–2026 · strength 0.65
  11. Daisuke Hashimoto · 3 shared papers, 2025–2026 · strength 0.65
  12. Haruyoshi Tanaka · 3 shared papers, 2025–2026 · strength 0.64
  13. Shinji Mii · 2 shared papers, 2026 · strength 0.45
  14. Ryo Ashida · 2 shared papers, 2026 · strength 0.45
  15. Nobumasa Mizuno · 2 shared papers, 2026 · strength 0.45
  16. Motokazu Sugimoto · 2 shared papers, 2026 · strength 0.45
  17. Katsuhiko Uesaka · 2 shared papers, 2026 · strength 0.45
  18. Hirochika Toyama · 2 shared papers, 2026 · strength 0.45
  19. Atsuyuki Maeda · 2 shared papers, 2026 · strength 0.45
  20. Tomoki Ebata · 2 shared papers, 2025–2026 · strength 0.42
  21. Yosuke Inoue · 2 shared papers, 2026 · strength 0.41
  22. Teiichi Sugiura · 2 shared papers, 2026 · strength 0.41
  23. Kenjiro Okada · 2 shared papers, 2026 · strength 0.41
  24. Ryuta Shintakuya · 2 shared papers, 2026 · strength 0.41
  25. Masamichi Mizuma · 2 shared papers, 2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.